Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,202,295.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Up 0.4%

Shares of NASDAQ:UTHR opened at $549.87 on Friday. The company’s fifty day moving average is $568.23 and its two-hundred day moving average is $518.83. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market cap of $23.34 billion, a P/E ratio of 20.30, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the firm earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on UTHR. UBS Group upped their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Raymond James Financial began coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently bought and sold shares of UTHR. Torren Management LLC acquired a new position in United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.